New targeted lung cancer drug produces 'dramatic' symptom improvement; Early-stage trial shows promise against tumors driven by ALK gene alteration

A clinical trial of a new targeted drug has provided powerful evidence that it can halt or reverse the growth of lung tumors characterized by a specific genetic abnormality. The multi-institutional research team reports that daily doses of crizotinib shrank the tumors of more than half of a group patients whose tumors were driven by alterations in the anaplastic lymphoma kinase gene and suppressed tumor growth in another one-third of study participants.

Read the whole article on Science Daily

More from Science Daily